FDA guidance
Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for…
FDA guidance · Draft · issued Nov 26, 2024
Key facts
| Title | Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products |
|---|---|
| Status | Draft |
| Issue date | Nov 26, 2024 |
| Center | Office of the Commissioner |
| Issuing office | Oncology Center of Excellence, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Biologics, Drugs |
| Docket number | FDA-2024-D-4643 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents